Region:
All editions →MethodologyUpdated · October 2026
GHRH analogue research

CJC-1295.
8 vendors · €22–89

GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.

Clinical-stageLyophilised vialAlso known as:Mod GRF 1-29 · Modified GRF (1-29) · CJC-1295 DAC · CJC-1295 with DAC · CJC-1295 without DAC · DAC:GRF
Compound specification
Half-life
DAC form 5.8–8.1 days (human; Teichman et al. 2006) · no-DAC form: no peer-reviewed figure found
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
2 mg, 5 mg, 10 mg
What it is

The compound. Origin, research and regulatory reality.

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29), developed by ConjuChem Biotechnologies in the mid-2000s. It is a tetrasubstituted form of GHRH(1-29) (Jetté et al., 2005). The name covers two chemically distinct forms.

A Phase II study in healthy adults (Teichman et al., 2006, J Clin Endocrinol Metab) reported that subcutaneous CJC-1295 with DAC produced sustained, dose-dependent increases in GH and IGF-I over several weeks. ConjuChem's Phase II programme in HIV-associated visceral adiposity (NCT00267527) was terminated in 2006 and development did not resume; the trials reviewed here did not evaluate body-composition or performance outcomes.

Neither form is approved as a medicine anywhere; both are sold research-use-only, and GHRH analogues are named on the WADA Prohibited List under S2, prohibited at all times for tested athletes. The DAC form carries a maleimidopropionyl linker that binds serum albumin, giving a reported half-life of 5.8–8.1 days (Teichman et al., 2006). The no-DAC form (Mod GRF 1-29) lacks the linker and is cleared far faster; we found no peer-reviewed half-life figure for it.

Live vendor register · grouped by strength

Every vendor. Cheapest per mg first, kits listed separately.

CJC-1295 · price per mg
12 listings · unflagged vendors first · Listings data last updated October 2026

Best price per mg: Pepsup 5 mg (no-DAC) at €6.00/mg. Kits go lower — €4.00/mg, sold only in multi-vial packs.

2 mg (DAC)

1 listing
01
Direct Peptides EUVID-DIRECT-P · UK network · from £24.2
2 mg (DAC)
99%
HPLC badge only (no reports published)
In stock
10–14 days
€14.00/mg
€28

2 mg (no-DAC)

2 listings
01
Direct Peptides EUVID-DIRECT-P · UK network · from £18.74
2 mg (no-DAC)
99%
HPLC badge only (no reports published)
In stock
10–14 days
€11.00/mg
€22
02
SwissChemsVID-SWISSCHE · US dispatch · from $42.95
2 mg (no-DAC)
99%
HPLC (Janoshik)
In stock
2–3 weeks
€18.50/mg
€37

5 mg (DAC)

2 listings
01
Particle PeptidesVID-PARTICLE · SK dispatch
5 mg (DAC)
99%
COA PDF (method unstated)
In stock
2–7 days
€11.00/mg
€55
02
Adria ScienceVID-ADRIA-SC · SI/CZ dispatch
5 mg (DAC)
98.6%
Liquilabs per-lot COA · USP<85>
In stock
Dispatch 1–3 days
€17.80/mg
€89

5 mg (no-DAC)

3 listings
01
PepsupVID-PEPSUP · NL dispatch · €29.99
5 mg (no-DAC)
99%
No COA published (mfr claim 99%+)
In stock
NL 1–2 d · EU 2–5 d
€6.00/mg
€30
02
PEAK_PEPTIDEVID-PEAK-PEP · AT dispatch
5 mg (no-DAC)
99%
COA in progress (mfr ≥99%)
In stock
Dispatch 24–48 h
€7.40/mg
€37
03
Particle PeptidesVID-PARTICLE · SK dispatch
5 mg (no-DAC)
99%
COA PDF (method unstated)
In stock
2–7 days
€8.20/mg
€41

Kits · multi-vial packs, price per vial

01
QSC PeptidesPickVID-QSC-PEPT · Kit of 10 · from $230
5 mg (no-DAC)kit of 10
99%
HPLC · MS · Janoshik
In stock
7–14 days (international)
€4.00/mg
€20≈ €200 per kit
02
QSC PeptidesPickVID-QSC-PEPT · Kit of 10 · from $220
2 mg (DAC)kit of 10
99%
HPLC · MS · Janoshik
In stock
7–14 days (CN warehouse)
€9.50/mg
€19≈ €190 per kit

Flagged vendors · documented, never recommended

01
CertaPeptidesVID-CERTAPEP · RO dispatch
2 mg (no-DAC)
98%
Janoshik (selected lots)
In stock
3–7 days
€15.00/mg
€30
02
CertaPeptidesVID-CERTAPEP · RO dispatch · 2 mg out of stock
5 mg (DAC)
98%
Janoshik (selected lots)
In stock
3–7 days
€17.20/mg
€86
Representative literature

Research context. Recent peer-reviewed work.

2005 · Endocrinology
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
2006 · J. Clin. Endocrinol. Metab.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006 · J. Clin. Endocrinol. Metab.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Common questions

Frequently asked.

Is CJC-1295 legal to buy?

It is sold research-use-only, for laboratory research rather than human use. Neither the DAC nor the no-DAC form is an approved medicine anywhere, and RUO labelling does not authorise personal administration.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form binds blood albumin and persisted for 5.8–8.1 days in the Phase II trial, giving sustained GH/IGF-1 elevation. The no-DAC form (Mod GRF 1-29) lacks that linker and is cleared far faster; we found no peer-reviewed half-life figure for it.

What should a CoA show for CJC-1295?

Confirm which form was tested: the DAC form carries an extra lysine-linker residue, so the two forms differ in mass and the LC-MS result must match the form named on the label. Then check HPLC purity, lot number and an independent lab name.

Same research area

Similar compounds.

GH secretagogue research

Ipamorelin

Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
8 vendors€14–45
Fat metabolism research fragment

AOD-9604

Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
6 vendors€21–60
Triple hormone agonist research

Retatrutide

Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
6 vendors€70–122
GIP/GLP-1 dual agonist research

Tirzepatide

Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
4 vendors€40–90
Amylin analogue research

Cagrilintide

Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.
2 vendors€103
GLP-1 receptor agonist research

Semaglutide

GLP-1 receptor agonist, FDA- and EMA-approved as Ozempic, Wegovy and Rybelsus. Research-vial semaglutide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
1 vendor€13per vial · kits only
Long-form research guide

Weight Loss Research. Mechanism + protocols + safety.

Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models

Open the long-form guide for CJC-1295 →